| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |